help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0425
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
93/8/3165    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Hivert, M.-F.
Right arrow Articles by Meigs, J. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hivert, M.-F.
Right arrow Articles by Meigs, J. B.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Metabolism
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 8 3165-3172
Copyright © 2008 by The Endocrine Society

Associations of Adiponectin, Resistin, and Tumor Necrosis Factor-{alpha} with Insulin Resistance

Marie-France Hivert, Lisa M. Sullivan, Caroline S. Fox, David M. Nathan, Ralph B. D'Agostino, Sr., Peter W. F. Wilson and James B. Meigs

Department of Medicine (M.-F.H., J.B.M.), Harvard Medical School and the General Medicine Division, and Harvard Medical School and the Diabetes Center, Department of Medicine (D.M.N., J.B.M.), Massachusetts General Hospital, Boston, Massachusetts 02114; The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Department of Endocrinology and Metabolism (C.S.F.), Harvard Medical School and the Brigham and Women’s Hospital, and Department of Biostatistics (L.M.S.), and Department of Mathematics and Statistics/Consulting Unit (R.B.D.), Boston University School of Public Health, Boston, Massachusetts; Boston University, Boston, Massachusetts 02215; and Department of Medicine (P.W.F.W.), Cardiology Division, Emory University School of Medicine, Atlanta, Georgia 30306

Address all correspondence and requests for reprints to: James B. Meigs, M.D., M.P.H., General Medicine Division, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, Massachusetts 02114. E-mail: hjmeigs{at}partners.org.

Context: Adipose tissue-derived adipokines may contribute to insulin resistance.

Objective: We tested the hypothesis that adipokines are associated with insulin resistance in a community-based cohort and that associations are maintained in people with and without the metabolic syndrome (high vs. low risk of diabetes).

Design, Setting, and Participants: We studied a cross-sectional sample of 2356 individuals attending the seventh examination (1998–2001) of the Framingham Offspring Study. We measured levels of glucose, insulin, adiponectin, resistin, and TNF{alpha} in fasting blood samples and defined metabolic syndrome by updated National Cholesterol Education Program criteria. We used ANOVA to test associations of adipokines with insulin resistance and multivariable logistic regression models to assess joint associations of adipokines and metabolic syndrome with insulin resistance.

Main Outcome Measure: Homeostasis model (HOMA-IR), with insulin resistance defined by HOMA-IR greater than the 75th percentile, was measured.

Results: Age- and sex-adjusted HOMA-IR levels were inversely related to adiponectin (r = –0.40, P < 0.0001) and positively related to resistin (r = 0.13, P < 0.0001) and TNF{alpha} (r = 0.12, P < 0.0001). The prevalence of insulin resistance increased with decreasing tertiles of adiponectin (from 10.9% in the third to 42.5% in the first tertile; P < 0.0001) and increasing tertiles of resistin (from 19.3 to 30.9%; P < 0.0001) and TNF{alpha} (from 18.8 to 32.0%; P < 0.0001). Results were similar after adjustment for body mass index. These associations were present in individuals with or without the metabolic syndrome. In multivariable regression models, metabolic syndrome and adipokines individually and jointly were significantly associated with insulin resistance.

Conclusion: Adverse levels of adipokines are associated with insulin resistance in individuals at low or high diabetes risk.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
N. Rasouli and P. A. Kern
Adipocytokines and the Metabolic Complications of Obesity
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11_Supplement_1): s64 - s73.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society